Context Therapeutics, Inc. (CNTX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.38

From 52W high−89.04%

Volume1.08M

Market cap$33.82M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$0.38

From 52W high

−89.04%

Volume

1.08M

Market cap

$33.82M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.2x

P/E (TTM)

—

RSI (14)

40.9

MomentumView details →

1D Return

−3.99%

YTD Return

−73.29%

SummaryUpdated Jun 1, 2026

Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Philadelphia, Pennsylvania. The company went public in October 2021 and focuses exclusively on developing innovative cancer treatments specifically for women. Context Therapeutics operates as a pre-revenue biotechnology company, dedicating its resources to advancing two primary drug candidates through clinical trials targeting female hormone-dependent cancers and gynecologic malignancies.

Ask drillr about Context Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−120.40%

ROA (TTM)

−99.62%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−14.60%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+17.39%

EBITDA YoY

−26.13%

MomentumView details →

1D Return

−3.99%

YTD Return

−73.29%

1Y Return

−59.44%

RSI (14)

40.9

vs 50D SMA

−21.47%

vs 200D SMA

−75.51%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

5.81x

Quick Ratio

5.81x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.15

EPS Surprise

−62.80%

Beats (12Q)

4/12

Next Q EPS Est

−$0.11

Avg Surprise (4Q)

−19.04%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−45.96M

Op. CF (TTM)

−33.97M

Next earningsNov 4, 2026 →

Latest newsMore news →

Context Therapeutics announced that the first patient has been dosed in the Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody, for solid tumors.11d ago

Context Therapeutics released interim Phase 1 data for CTIM-76, a CLDN6 x CD3 T-cell engaging bispecific antibody, in patients with advanced platinum-resistant ovarian cancer.97d ago

Similar companies

Genenta Science S.p.A.GNTA TAO Synergies Inc.TAOX Aligos Therapeutics, Inc.ALGS Filana Therapeutics, Inc.FLNA Leap Therapeutics, Inc.LPTX OmniAb, Inc.OABIW Find similar companies →

Latest newsMore news →

Context Therapeutics announced that the first patient has been dosed in the Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody, for solid tumors.11d ago Context Therapeutics released interim Phase 1 data for CTIM-76, a CLDN6 x CD3 T-cell engaging bispecific antibody, in patients with advanced platinum-resistant ovarian cancer.97d ago